Antares Pharma Inc. announced Thursday that the U.S. Food and Drug Administration had found deficiencies in the drug Xyosted (testosterone enanthate) during its review process, the company said in a statement. Shares plummeted more than 30% to $2.60 after hours. The FDA did not specify what the deficiencies are but did say that it would prevent moving forward with labeling and postmarketing requirements and commitments at this point. Antares submitted the Xyosted application in December 2016. Antares stock was up 60% this year, based on today’s closing price, with the S&P 500 index up 14.1%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Latest posts by Market Watch (see all)
- The Wall Street Journal: FBI Deputy Director McCabe fired two days before retirement date - March 16, 2018
- Financial News: Freeze the assets of Putin’s allies, U.K, U.S. lawmakers say: it’s ‘the only way to change the behavior of evil regimes’ - March 16, 2018
- Qualcomm shuts Jacobs out of board election on takeover plans - March 16, 2018